Study of Descartes-30 in Acute Respiratory Distress Syndrome

Phase 1TerminatedNCT04524962

Cartesian Therapeutics12 enrolled

Overview

Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acute Respiratory Distress Syndrome Covid19

Interventions

Descartes 30BIOLOGICAL

Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must be 18 years of age or older at the time of enrollment * Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS Exclusion Criteria: * Patient is currently enrolled into another therapeutic clinical trial with an experimental therapy that has not received marketing approval by U.S. FDA. * Patient is in moribund state with expected survival \<24 hours.

Locations (2)

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

University of Maryland Medical Center Medical Center

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

To Assess the Safety of Descartes-30 in Patients With Moderate-to-severe ARDS.

Safety will be determined principally by assessment of adverse events (AEs) and serious adverse events (SAEs).

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.